Characteristics and short- and long-term direct medical costs among adults with timely and delayed presentation for HIV care in the Netherlands
In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and long-term costs of HIV-care based on time of presentation and identify other factors contributing to higher costs in the first and fifth year af...
Gespeichert in:
| Veröffentlicht in: | PloS one Jg. 18; H. 2; S. e0280877 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Public Library of Science
08.02.2023
Public Library of Science (PLoS) |
| Schlagworte: | |
| ISSN: | 1932-6203, 1932-6203 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and long-term costs of HIV-care based on time of presentation and identify other factors contributing to higher costs in the first and fifth year after antiretroviral therapy (ART) initiation.
We included ATHENA cohort data which prospectively includes 98% of PLWH in the Netherlands. PLWH who initiated ART in 2013 were included and followed over five years. PLWH were divided in three categories based on CD4 cell-count at time of ART initiation: timely presentation (CD4>350cells/μL), late presentation (CD4 200-350cells/μL or >350cells/μL with AIDS-defining illness) and very late presentation (CD4<200cells/μL). The total HIV-care cost was calculated distinguishing ART medication and non-ART medication costs (hospitalization, outpatient clinic visits, co-medications, and HIV-laboratory tests).
From 1,296 PLWH, 273 (21%) presented late and 179 (14%) very late. Nearly half of those who entered HIV-care in a very late stage were of non-Dutch origin, with 21% originating from sub-Saharan Africa. The mean cost per patient in the first year was €12,902 (SD€11,098), of which about two-thirds due to ART (€8,250 (SD€3,142)). ART costs in the first and fifth year were comparable regardless of time of presentation. During the first year on treatment, non-ART medication costs were substantially higher among those with late presentation (€4,749 (SD€8,009)) and very late presentation (€15,886 (SD€ 21,834)), compared with timely presentation (€2,407(SD€4,511)). Higher non-ART costs were attributable to hospitalization and co-medication. The total non-ART costs incurred across five years on treatment were 56% and 246% higher for late and very late presentation respectively as compared to timely presentation.
Very late presentation is associated with substantial costs, with non-ART costs nearly seven times higher than for those presenting timely. Hospitalization and co-medication costs are likely to continue to drive higher costs for individuals with late presentation into the future. Programs that identify individuals earlier will therefore likely provide significant short- and long-term health cost savings. |
|---|---|
| AbstractList | In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and long-term costs of HIV-care based on time of presentation and identify other factors contributing to higher costs in the first and fifth year after antiretroviral therapy (ART) initiation.INTRODUCTIONIn Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and long-term costs of HIV-care based on time of presentation and identify other factors contributing to higher costs in the first and fifth year after antiretroviral therapy (ART) initiation.We included ATHENA cohort data which prospectively includes 98% of PLWH in the Netherlands. PLWH who initiated ART in 2013 were included and followed over five years. PLWH were divided in three categories based on CD4 cell-count at time of ART initiation: timely presentation (CD4>350cells/μL), late presentation (CD4 200-350cells/μL or >350cells/μL with AIDS-defining illness) and very late presentation (CD4<200cells/μL). The total HIV-care cost was calculated distinguishing ART medication and non-ART medication costs (hospitalization, outpatient clinic visits, co-medications, and HIV-laboratory tests).MATERIAL AND METHODSWe included ATHENA cohort data which prospectively includes 98% of PLWH in the Netherlands. PLWH who initiated ART in 2013 were included and followed over five years. PLWH were divided in three categories based on CD4 cell-count at time of ART initiation: timely presentation (CD4>350cells/μL), late presentation (CD4 200-350cells/μL or >350cells/μL with AIDS-defining illness) and very late presentation (CD4<200cells/μL). The total HIV-care cost was calculated distinguishing ART medication and non-ART medication costs (hospitalization, outpatient clinic visits, co-medications, and HIV-laboratory tests).From 1,296 PLWH, 273 (21%) presented late and 179 (14%) very late. Nearly half of those who entered HIV-care in a very late stage were of non-Dutch origin, with 21% originating from sub-Saharan Africa. The mean cost per patient in the first year was €12,902 (SD€11,098), of which about two-thirds due to ART (€8,250 (SD€3,142)). ART costs in the first and fifth year were comparable regardless of time of presentation. During the first year on treatment, non-ART medication costs were substantially higher among those with late presentation (€4,749 (SD€8,009)) and very late presentation (€15,886 (SD€ 21,834)), compared with timely presentation (€2,407(SD€4,511)). Higher non-ART costs were attributable to hospitalization and co-medication. The total non-ART costs incurred across five years on treatment were 56% and 246% higher for late and very late presentation respectively as compared to timely presentation.RESULTSFrom 1,296 PLWH, 273 (21%) presented late and 179 (14%) very late. Nearly half of those who entered HIV-care in a very late stage were of non-Dutch origin, with 21% originating from sub-Saharan Africa. The mean cost per patient in the first year was €12,902 (SD€11,098), of which about two-thirds due to ART (€8,250 (SD€3,142)). ART costs in the first and fifth year were comparable regardless of time of presentation. During the first year on treatment, non-ART medication costs were substantially higher among those with late presentation (€4,749 (SD€8,009)) and very late presentation (€15,886 (SD€ 21,834)), compared with timely presentation (€2,407(SD€4,511)). Higher non-ART costs were attributable to hospitalization and co-medication. The total non-ART costs incurred across five years on treatment were 56% and 246% higher for late and very late presentation respectively as compared to timely presentation.Very late presentation is associated with substantial costs, with non-ART costs nearly seven times higher than for those presenting timely. Hospitalization and co-medication costs are likely to continue to drive higher costs for individuals with late presentation into the future. Programs that identify individuals earlier will therefore likely provide significant short- and long-term health cost savings.CONCLUSIONVery late presentation is associated with substantial costs, with non-ART costs nearly seven times higher than for those presenting timely. Hospitalization and co-medication costs are likely to continue to drive higher costs for individuals with late presentation into the future. Programs that identify individuals earlier will therefore likely provide significant short- and long-term health cost savings. In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and long-term costs of HIV-care based on time of presentation and identify other factors contributing to higher costs in the first and fifth year after antiretroviral therapy (ART) initiation. We included ATHENA cohort data which prospectively includes 98% of PLWH in the Netherlands. PLWH who initiated ART in 2013 were included and followed over five years. PLWH were divided in three categories based on CD4 cell-count at time of ART initiation: timely presentation (CD4>350cells/[mu]L), late presentation (CD4 200-350cells/[mu]L or >350cells/[mu]L with AIDS-defining illness) and very late presentation (CD4<200cells/[mu]L). The total HIV-care cost was calculated distinguishing ART medication and non-ART medication costs (hospitalization, outpatient clinic visits, co-medications, and HIV-laboratory tests). From 1,296 PLWH, 273 (21%) presented late and 179 (14%) very late. Nearly half of those who entered HIV-care in a very late stage were of non-Dutch origin, with 21% originating from sub-Saharan Africa. The mean cost per patient in the first year was [euro]12,902 (SD[euro]11,098), of which about two-thirds due to ART ([euro]8,250 (SD[euro]3,142)). ART costs in the first and fifth year were comparable regardless of time of presentation. During the first year on treatment, non-ART medication costs were substantially higher among those with late presentation ([euro]4,749 (SD[euro]8,009)) and very late presentation ([euro]15,886 (SD[euro] 21,834)), compared with timely presentation ([euro]2,407(SD[euro]4,511)). Higher non-ART costs were attributable to hospitalization and co-medication. The total non-ART costs incurred across five years on treatment were 56% and 246% higher for late and very late presentation respectively as compared to timely presentation. Very late presentation is associated with substantial costs, with non-ART costs nearly seven times higher than for those presenting timely. Hospitalization and co-medication costs are likely to continue to drive higher costs for individuals with late presentation into the future. Programs that identify individuals earlier will therefore likely provide significant short- and long-term health cost savings. Introduction In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and long-term costs of HIV-care based on time of presentation and identify other factors contributing to higher costs in the first and fifth year after antiretroviral therapy (ART) initiation. Material and methods We included ATHENA cohort data which prospectively includes 98% of PLWH in the Netherlands. PLWH who initiated ART in 2013 were included and followed over five years. PLWH were divided in three categories based on CD4 cell-count at time of ART initiation: timely presentation (CD4>350cells/μL), late presentation (CD4 200-350cells/μL or >350cells/μL with AIDS-defining illness) and very late presentation (CD4<200cells/μL). The total HIV-care cost was calculated distinguishing ART medication and non-ART medication costs (hospitalization, outpatient clinic visits, co-medications, and HIV-laboratory tests). Results From 1,296 PLWH, 273 (21%) presented late and 179 (14%) very late. Nearly half of those who entered HIV-care in a very late stage were of non-Dutch origin, with 21% originating from sub-Saharan Africa. The mean cost per patient in the first year was €12,902 (SD€11,098), of which about two-thirds due to ART (€8,250 (SD€3,142)). ART costs in the first and fifth year were comparable regardless of time of presentation. During the first year on treatment, non-ART medication costs were substantially higher among those with late presentation (€4,749 (SD€8,009)) and very late presentation (€15,886 (SD€ 21,834)), compared with timely presentation (€2,407(SD€4,511)). Higher non-ART costs were attributable to hospitalization and co-medication. The total non-ART costs incurred across five years on treatment were 56% and 246% higher for late and very late presentation respectively as compared to timely presentation. Conclusion Very late presentation is associated with substantial costs, with non-ART costs nearly seven times higher than for those presenting timely. Hospitalization and co-medication costs are likely to continue to drive higher costs for individuals with late presentation into the future. Programs that identify individuals earlier will therefore likely provide significant short- and long-term health cost savings. Introduction In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and long-term costs of HIV-care based on time of presentation and identify other factors contributing to higher costs in the first and fifth year after antiretroviral therapy (ART) initiation. Material and methods We included ATHENA cohort data which prospectively includes 98% of PLWH in the Netherlands. PLWH who initiated ART in 2013 were included and followed over five years. PLWH were divided in three categories based on CD4 cell-count at time of ART initiation: timely presentation (CD4>350cells/[mu]L), late presentation (CD4 200-350cells/[mu]L or >350cells/[mu]L with AIDS-defining illness) and very late presentation (CD4<200cells/[mu]L). The total HIV-care cost was calculated distinguishing ART medication and non-ART medication costs (hospitalization, outpatient clinic visits, co-medications, and HIV-laboratory tests). Results From 1,296 PLWH, 273 (21%) presented late and 179 (14%) very late. Nearly half of those who entered HIV-care in a very late stage were of non-Dutch origin, with 21% originating from sub-Saharan Africa. The mean cost per patient in the first year was [euro]12,902 (SD[euro]11,098), of which about two-thirds due to ART ([euro]8,250 (SD[euro]3,142)). ART costs in the first and fifth year were comparable regardless of time of presentation. During the first year on treatment, non-ART medication costs were substantially higher among those with late presentation ([euro]4,749 (SD[euro]8,009)) and very late presentation ([euro]15,886 (SD[euro] 21,834)), compared with timely presentation ([euro]2,407(SD[euro]4,511)). Higher non-ART costs were attributable to hospitalization and co-medication. The total non-ART costs incurred across five years on treatment were 56% and 246% higher for late and very late presentation respectively as compared to timely presentation. Conclusion Very late presentation is associated with substantial costs, with non-ART costs nearly seven times higher than for those presenting timely. Hospitalization and co-medication costs are likely to continue to drive higher costs for individuals with late presentation into the future. Programs that identify individuals earlier will therefore likely provide significant short- and long-term health cost savings. In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and long-term costs of HIV-care based on time of presentation and identify other factors contributing to higher costs in the first and fifth year after antiretroviral therapy (ART) initiation. We included ATHENA cohort data which prospectively includes 98% of PLWH in the Netherlands. PLWH who initiated ART in 2013 were included and followed over five years. PLWH were divided in three categories based on CD4 cell-count at time of ART initiation: timely presentation (CD4>350cells/μL), late presentation (CD4 200-350cells/μL or >350cells/μL with AIDS-defining illness) and very late presentation (CD4<200cells/μL). The total HIV-care cost was calculated distinguishing ART medication and non-ART medication costs (hospitalization, outpatient clinic visits, co-medications, and HIV-laboratory tests). From 1,296 PLWH, 273 (21%) presented late and 179 (14%) very late. Nearly half of those who entered HIV-care in a very late stage were of non-Dutch origin, with 21% originating from sub-Saharan Africa. The mean cost per patient in the first year was €12,902 (SD€11,098), of which about two-thirds due to ART (€8,250 (SD€3,142)). ART costs in the first and fifth year were comparable regardless of time of presentation. During the first year on treatment, non-ART medication costs were substantially higher among those with late presentation (€4,749 (SD€8,009)) and very late presentation (€15,886 (SD€ 21,834)), compared with timely presentation (€2,407(SD€4,511)). Higher non-ART costs were attributable to hospitalization and co-medication. The total non-ART costs incurred across five years on treatment were 56% and 246% higher for late and very late presentation respectively as compared to timely presentation. Very late presentation is associated with substantial costs, with non-ART costs nearly seven times higher than for those presenting timely. Hospitalization and co-medication costs are likely to continue to drive higher costs for individuals with late presentation into the future. Programs that identify individuals earlier will therefore likely provide significant short- and long-term health cost savings. Introduction In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and long-term costs of HIV-care based on time of presentation and identify other factors contributing to higher costs in the first and fifth year after antiretroviral therapy (ART) initiation. Material and methods We included ATHENA cohort data which prospectively includes 98% of PLWH in the Netherlands. PLWH who initiated ART in 2013 were included and followed over five years. PLWH were divided in three categories based on CD4 cell-count at time of ART initiation: timely presentation (CD4>350cells/μL), late presentation (CD4 200-350cells/μL or >350cells/μL with AIDS-defining illness) and very late presentation (CD4<200cells/μL). The total HIV-care cost was calculated distinguishing ART medication and non-ART medication costs (hospitalization, outpatient clinic visits, co-medications, and HIV-laboratory tests). Results From 1,296 PLWH, 273 (21%) presented late and 179 (14%) very late. Nearly half of those who entered HIV-care in a very late stage were of non-Dutch origin, with 21% originating from sub-Saharan Africa. The mean cost per patient in the first year was €12,902 (SD€11,098), of which about two-thirds due to ART (€8,250 (SD€3,142)). ART costs in the first and fifth year were comparable regardless of time of presentation. During the first year on treatment, non-ART medication costs were substantially higher among those with late presentation (€4,749 (SD€8,009)) and very late presentation (€15,886 (SD€ 21,834)), compared with timely presentation (€2,407(SD€4,511)). Higher non-ART costs were attributable to hospitalization and co-medication. The total non-ART costs incurred across five years on treatment were 56% and 246% higher for late and very late presentation respectively as compared to timely presentation. Conclusion Very late presentation is associated with substantial costs, with non-ART costs nearly seven times higher than for those presenting timely. Hospitalization and co-medication costs are likely to continue to drive higher costs for individuals with late presentation into the future. Programs that identify individuals earlier will therefore likely provide significant short- and long-term health cost savings. |
| Audience | Academic |
| Author | Popping, Stephanie van Sighem, Ard Nichols, Brooke E. Verbon, Annelies van de Vijver, David A. M. C. Reiss, Peter Boucher, Charles A. B. Versteegh, Lisbeth Geerlings, Suzanne |
| AuthorAffiliation | 6 Stichting HIV Monitoring, Amsterdam, the Netherlands 3 Department of Global Health, Boston University, Boston, MA, United States of America University of Catania: Universita degli Studi di Catania, ITALY 9 Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands 5 Department of Medical Microbiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands 4 Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa 2 Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, the Netherlands 7 Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands 1 Department of Viroscience, Erasmus Medical Center, Rott |
| AuthorAffiliation_xml | – name: 6 Stichting HIV Monitoring, Amsterdam, the Netherlands – name: 2 Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, the Netherlands – name: University of Catania: Universita degli Studi di Catania, ITALY – name: 1 Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands – name: 9 Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands – name: 4 Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa – name: 3 Department of Global Health, Boston University, Boston, MA, United States of America – name: 8 Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands – name: 7 Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands – name: 5 Department of Medical Microbiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands |
| Author_xml | – sequence: 1 givenname: Stephanie orcidid: 0000-0002-8959-4671 surname: Popping fullname: Popping, Stephanie – sequence: 2 givenname: Lisbeth surname: Versteegh fullname: Versteegh, Lisbeth – sequence: 3 givenname: Brooke E. surname: Nichols fullname: Nichols, Brooke E. – sequence: 4 givenname: David A. M. C. surname: van de Vijver fullname: van de Vijver, David A. M. C. – sequence: 5 givenname: Ard orcidid: 0000-0002-6656-0516 surname: van Sighem fullname: van Sighem, Ard – sequence: 6 givenname: Peter orcidid: 0000-0001-7896-6428 surname: Reiss fullname: Reiss, Peter – sequence: 7 givenname: Suzanne surname: Geerlings fullname: Geerlings, Suzanne – sequence: 8 givenname: Charles A. B. surname: Boucher fullname: Boucher, Charles A. B. – sequence: 9 givenname: Annelies surname: Verbon fullname: Verbon, Annelies |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36753495$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk2trFDEUhgdR7EX_gWhAEP2way4zmcQPQilqF4oFL_0azmYyOymZyZpk1P4K_7LZ7rR0SxEZmEnOed6Tycs5B8XDwQ-mKJ4RPCesJm8v_BgGcPN1Ds8xFVjU9YNin0hGZ5xi9vDWeq84iPEC44oJzh8Xe4zXFStltV_8Oe4ggE4m2JisjgiGBsXOhzS7Wjo_rGY526PGBqMT6k1jNTikfUyZ7nMeQTO6vPllU4eS7Y27vNI2xsGladA6mGiGBMn6AbU-oJPFOdIQDLIDSp1Bn01-B5c18UnxqAUXzdPpe1h8__jh2_HJ7PTs0-L46HSmuaRpJqVphKi0ENBUraDAMGtoVcmSs4powoFQDqVkspWlaHljyiUI0IbVragoZYfFi23dtfNRTV5GReu6LDnGZEMstkTj4UKtg-0hXCoPVl0FfFgpCNkyZxTIZQ3EyIaytpQglrXkpGZAMJdtK9tc6_102rjMBursRgC3U3Q3M9hOrfxPJSWuBalygddTgeB_jCYm1duojcueGT9O_y25YHVGX95B77_dRK0gX8AOrc_n6k1RdVQzTiWVmGVqfg-Vn8b0VufGa22O7wje7Agyk8zvtIIxRrX4-uX_2bPzXfbVLbYz4FIXvRs3LRV3wee3nb6x-LrjM1BuAR18jMG0NwjBajNY13apzWCpabCy7N0dmbbbjs6OWPdv8V-qfCob |
| CitedBy_id | crossref_primary_10_3389_fpubh_2024_1334881 crossref_primary_10_3390_microorganisms12020254 crossref_primary_10_1038_s41598_024_73648_6 crossref_primary_10_1002_jia2_26516 crossref_primary_10_1016_j_cmi_2025_02_036 crossref_primary_10_1093_eurpub_ckaf057 crossref_primary_10_1186_s12889_024_18499_6 |
| Cites_doi | 10.1097/QAD.0000000000000382 10.1056/NEJMoa1506816 10.1136/bmjopen-2018-022516 10.1007/s10461-018-2082-9 10.1097/01.aids.0000233579.79714.8d 10.1016/j.vhri.2014.07.005 10.1111/hiv.12430 10.1111/hiv.13121 10.1177/0956462418770014 10.7448/IAS.18.1.20317 10.1111/j.1468-1293.2004.00193.x 10.1371/journal.pone.0142576 10.1097/QCO.0000000000000415 10.7861/clinmedicine.16-2-175 10.1111/j.1468-1293.2010.00857.x 10.1016/S0140-6736(09)60612-7 10.1186/s12879-017-2279-y 10.1371/journal.pone.0052845 10.1136/sextrans-2018-053583 10.1186/s12879-021-06183-8 10.1016/j.eclinm.2021.100877 10.1186/s12981-016-0129-4 10.1097/MLR.0b013e3181f81c4a 10.1521/aeap.14.1.17.24333 10.3109/00365548.2011.626440 10.1016/S1470-2045(09)70282-7 10.1111/hiv.12686 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2023 Popping et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. COPYRIGHT 2023 Public Library of Science 2023 Popping et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023 Popping et al 2023 Popping et al 2023 Popping et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Copyright: © 2023 Popping et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: COPYRIGHT 2023 Public Library of Science – notice: 2023 Popping et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023 Popping et al 2023 Popping et al – notice: 2023 Popping et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | on behalf of the ATHENA observational cohort ATHENA observational cohort |
| CorporateAuthor_xml | – name: on behalf of the ATHENA observational cohort – name: ATHENA observational cohort |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0280877 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Database (1962 - current) Agricultural & Environmental Science Collection ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database (ProQuest) Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Agricultural Science Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Public Health |
| DocumentTitleAlternate | Cost of late presentation of HIV |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2774460012 oai_doaj_org_article_a9b7a1e9d23f49a8b796173a1069ff9f PMC9907815 A736292903 36753495 10_1371_journal_pone_0280877 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Netherlands Europe United States |
| GeographicLocations_xml | – name: Netherlands – name: Europe – name: United States |
| GrantInformation_xml | – fundername: ; grantid: 215001269 – fundername: ; grantid: SDD 343462 – fundername: ; grantid: 771290 – fundername: ; grantid: 14-0614-ViiV |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ADRAZ ALIPV BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI RC3 7X8 PUEGO 5PM AAPBV ABPTK |
| ID | FETCH-LOGICAL-c692t-99ed885c88ad5f82a303d255946351c16a126a4939f948f6de4ba8ace37f85223 |
| IEDL.DBID | P5Z |
| ISICitedReferencesCount | 9 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000966728400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1932-6203 |
| IngestDate | Sun Oct 01 00:11:32 EDT 2023 Fri Oct 03 12:50:35 EDT 2025 Tue Nov 04 02:07:10 EST 2025 Thu Oct 02 12:05:09 EDT 2025 Tue Oct 07 07:45:34 EDT 2025 Sat Nov 29 12:59:15 EST 2025 Sat Nov 29 10:16:16 EST 2025 Wed Nov 26 11:28:03 EST 2025 Wed Nov 26 11:29:09 EST 2025 Thu May 22 21:22:25 EDT 2025 Thu Apr 03 07:03:25 EDT 2025 Sat Nov 29 03:40:52 EST 2025 Tue Nov 18 21:53:42 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | Copyright: © 2023 Popping et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-99ed885c88ad5f82a303d255946351c16a126a4939f948f6de4ba8ace37f85223 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: DvdV reports unrestricted research grant from Gilead Sciences, Merck Sharp & Dohm, ViiV and Janssen Pharmaceuticals. CAB reports personal fees from speaker honoraria from ViiV outside the submitted work; AvS reports grants from Dutch Ministry of Health, Welfare and Sport, during the conduct of the study; grants from European Centre for Disease Prevention and Control, outside the submitted work. PR reports independent scientific grant support from Gilead Sciences, Merck Sharp & Dohm, and ViiV Healthcare through his institution; scientific advisory board participation for Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohm., and Teva Pharmaceutical Industries Ltd., for which his institution has received remuneration. SP, LV, BN, SG, AV have nothing to disclose. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Data can be shared upon request to the corresponding author. Membership of the ATHENA observational cohort is listed in the Acknowledgments. |
| ORCID | 0000-0002-6656-0516 0000-0001-7896-6428 0000-0002-8959-4671 |
| OpenAccessLink | https://www.proquest.com/docview/2774460012?pq-origsite=%requestingapplication% |
| PMID | 36753495 |
| PQID | 2774460012 |
| PQPubID | 1436336 |
| PageCount | e0280877 |
| ParticipantIDs | plos_journals_2774460012 doaj_primary_oai_doaj_org_article_a9b7a1e9d23f49a8b796173a1069ff9f pubmedcentral_primary_oai_pubmedcentral_nih_gov_9907815 proquest_miscellaneous_2774496837 proquest_journals_2774460012 gale_infotracmisc_A736292903 gale_infotracacademiconefile_A736292903 gale_incontextgauss_ISR_A736292903 gale_incontextgauss_IOV_A736292903 gale_healthsolutions_A736292903 pubmed_primary_36753495 crossref_primary_10_1371_journal_pone_0280877 crossref_citationtrail_10_1371_journal_pone_0280877 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-02-08 |
| PublicationDateYYYYMMDD | 2023-02-08 |
| PublicationDate_xml | – month: 02 year: 2023 text: 2023-02-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2023 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | Late presenters working group in CiE (pone.0280877.ref014) 2015; 20 L Bull (pone.0280877.ref026) 2016; 16 LG Ard van Sighem (pone.0280877.ref016) 2014 J Wilton (pone.0280877.ref023) 2019; 20 E Lord (pone.0280877.ref031) 2017; 18 A Antinori (pone.0280877.ref001) 2011; 12 SB Brogly (pone.0280877.ref006) 2002; 14 A.I. van Sighem (pone.0280877.ref018) 2020 ZN National Healthcare Institute (pone.0280877.ref020) 2022 SJ Bogers (pone.0280877.ref025) 2021; 21 IK Joore (pone.0280877.ref032) 2017; 17 C den Daas (pone.0280877.ref033) 2018; 29 BE Nichols (pone.0280877.ref034) 2015; 10 J Ross (pone.0280877.ref029) 2018; 31 C When To Start (pone.0280877.ref003) 2009; 373 HB Krentz (pone.0280877.ref011) 2012; 2012 ISS Group (pone.0280877.ref002) 2015; 373 M Guiguet (pone.0280877.ref004) 2009; 10 N Boubouchairopoulou (pone.0280877.ref010) 2014; 4 AK Sullivan (pone.0280877.ref024) 2013; 8 SEM van Opstal (pone.0280877.ref022) 2018; 22 G Marks (pone.0280877.ref007) 2006; 20 G Guaraldi (pone.0280877.ref009) 2017; 14 M Helleberg (pone.0280877.ref021) 2012; 44 SJ Bogers (pone.0280877.ref027) 2021; 35 MJ Gill (pone.0280877.ref028) 2021; 22 JP Bil (pone.0280877.ref030) 2019; 95 M Hleyhel (pone.0280877.ref005) 2014; 28 JA Fleishman (pone.0280877.ref012) 2010; 48 ECDC (pone.0280877.ref013) 2019; 2019 O. World Health (pone.0280877.ref017) 2013 TS Boender (pone.0280877.ref019) 2018; 8 A Hachfeld (pone.0280877.ref015) 2015; 18 HB Krentz (pone.0280877.ref008) 2004; 5 |
| References_xml | – volume: 20 issue: 47 year: 2015 ident: pone.0280877.ref014 article-title: Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. publication-title: Euro Surveill – year: 2020 ident: pone.0280877.ref018 article-title: The 2020 Monitoring report on Human Immunodeficiency Virus (HIV) Infection in the Netherlands. publication-title: Stichting HIV Monitoring (SHM), – volume: 28 start-page: 2109 issue: 14 year: 2014 ident: pone.0280877.ref005 article-title: Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort publication-title: Aids doi: 10.1097/QAD.0000000000000382 – volume: 373 start-page: 795 issue: 9 year: 2015 ident: pone.0280877.ref002 article-title: Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection publication-title: N Engl J Med doi: 10.1056/NEJMoa1506816 – volume: 8 start-page: e022516 issue: 9 year: 2018 ident: pone.0280877.ref019 article-title: AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort: cohort profile. publication-title: BMJ Open doi: 10.1136/bmjopen-2018-022516 – volume: 22 start-page: 2593 issue: 8 year: 2018 ident: pone.0280877.ref022 article-title: Late Presentation of HIV Infection in the Netherlands: Reasons for Late Diagnoses and Impact on Vocational Functioning publication-title: AIDS Behav doi: 10.1007/s10461-018-2082-9 – year: 2013 ident: pone.0280877.ref017 article-title: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection publication-title: Recommendations for a public health approach. World Health Organization – volume: 20 start-page: 1447 issue: 10 year: 2006 ident: pone.0280877.ref007 article-title: Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA publication-title: Aids doi: 10.1097/01.aids.0000233579.79714.8d – volume: 4 start-page: 82 year: 2014 ident: pone.0280877.ref010 article-title: Estimation of the Direct Cost of HIV-Infected Patients in Greece on an Annual Basis. publication-title: Value in Health Regional Issues. doi: 10.1016/j.vhri.2014.07.005 – volume: 18 start-page: 300 issue: 4 year: 2017 ident: pone.0280877.ref031 article-title: Evaluation of HIV testing recommendations in specialty guidelines for the management of HIV indicator conditions. publication-title: HIV Med. doi: 10.1111/hiv.12430 – volume: 2019 year: 2019 ident: pone.0280877.ref013 article-title: HIV/AIDS surveillance in Europe. publication-title: European Centre for Disease Prevention and Control (ECDC) – volume: 22 start-page: 723 issue: 8 year: 2021 ident: pone.0280877.ref028 article-title: Economic impact on direct healthcare costs of missing opportunities for diagnosing HIV within healthcare settings. publication-title: HIV Med doi: 10.1111/hiv.13121 – volume: 29 start-page: 1057 issue: 11 year: 2018 ident: pone.0280877.ref033 article-title: Increasing awareness and prompting HIV testing: Contributions of Amsterdam HIV Testing Week 2016 publication-title: Int J STD AIDS doi: 10.1177/0956462418770014 – volume: 2012 start-page: 757135 year: 2012 ident: pone.0280877.ref011 article-title: The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. publication-title: AIDS Res Treat – volume: 18 start-page: 20317 year: 2015 ident: pone.0280877.ref015 article-title: Reasons for late presentation to HIV care in Switzerland. publication-title: J Int AIDS Soc doi: 10.7448/IAS.18.1.20317 – volume: 5 start-page: 93 issue: 2 year: 2004 ident: pone.0280877.ref008 article-title: The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. publication-title: HIV Med. doi: 10.1111/j.1468-1293.2004.00193.x – volume: 10 start-page: e0142576 issue: 11 year: 2015 ident: pone.0280877.ref034 article-title: Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study. publication-title: PLoS One. doi: 10.1371/journal.pone.0142576 – volume: 31 start-page: 25 issue: 1 year: 2018 ident: pone.0280877.ref029 article-title: HIV outcomes among migrants from low-income and middle-income countries living in high-income countries: a review of recent evidence. publication-title: Curr Opin Infect Dis doi: 10.1097/QCO.0000000000000415 – year: 2022 ident: pone.0280877.ref020 article-title: Medication cost (Medicatie Kosten) Diemen – volume: 16 start-page: 175 issue: 2 year: 2016 ident: pone.0280877.ref026 article-title: HIV-indicator-condition-driven HIV testing: clinically effective but still rarely implemented. publication-title: Clin Med (Lond). doi: 10.7861/clinmedicine.16-2-175 – volume: 12 start-page: 61 issue: 1 year: 2011 ident: pone.0280877.ref001 article-title: Late presentation of HIV infection: a consensus definition. publication-title: HIV Med doi: 10.1111/j.1468-1293.2010.00857.x – volume: 373 start-page: 1352 issue: 9672 year: 2009 ident: pone.0280877.ref003 article-title: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies publication-title: Lancet doi: 10.1016/S0140-6736(09)60612-7 – volume: 17 start-page: 178 issue: 1 year: 2017 ident: pone.0280877.ref032 article-title: The importance of registration of sexual orientation and recognition of indicator conditions for an adequate HIV risk-assessment. publication-title: BMC Infect Dis doi: 10.1186/s12879-017-2279-y – volume: 8 start-page: e52845 issue: 1 year: 2013 ident: pone.0280877.ref024 article-title: Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). publication-title: PLoS One. doi: 10.1371/journal.pone.0052845 – volume: 95 start-page: 629 issue: 8 year: 2019 ident: pone.0280877.ref030 article-title: Usage of purchased self-tests for HIV infections among migrants living in the UK, France and the Netherlands: a cross-sectional study. publication-title: Sex Transm Infect. doi: 10.1136/sextrans-2018-053583 – volume: 21 start-page: 519 issue: 1 year: 2021 ident: pone.0280877.ref025 article-title: Promoting HIV indicator condition-guided testing in hospital settings (PROTEST 2.0): study protocol for a multicentre interventional study. publication-title: BMC Infectious Diseases. doi: 10.1186/s12879-021-06183-8 – volume: 35 start-page: 100877 year: 2021 ident: pone.0280877.ref027 article-title: Current evidence on the adoption of indicator condition guided testing for HIV in western countries: A systematic review and meta-analysis. publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2021.100877 – volume: 14 start-page: 8 issue: 1 year: 2017 ident: pone.0280877.ref009 article-title: Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study publication-title: AIDS Res Ther doi: 10.1186/s12981-016-0129-4 – volume: 48 start-page: 1071 issue: 12 year: 2010 ident: pone.0280877.ref012 article-title: The economic burden of late entry into medical care for patients with HIV infection. publication-title: Med Care doi: 10.1097/MLR.0b013e3181f81c4a – year: 2014 ident: pone.0280877.ref016 article-title: Monitoring Report 2014 publication-title: Human Immunodeficiency Virus (HIV) Infection in the Netherlands Amsterdam: Stichting HIV Monitoring – volume: 14 start-page: 17 issue: 1 year: 2002 ident: pone.0280877.ref006 article-title: HIV-positive notification and behavior changes in Montreal injection drug users publication-title: AIDS Educ Prev doi: 10.1521/aeap.14.1.17.24333 – volume: 44 start-page: 282 issue: 4 year: 2012 ident: pone.0280877.ref021 article-title: Late presenters, repeated testing, and missed opportunities in a Danish nationwide HIV cohort publication-title: Scand J Infect Dis doi: 10.3109/00365548.2011.626440 – volume: 10 start-page: 1152 issue: 12 year: 2009 ident: pone.0280877.ref004 article-title: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70282-7 – volume: 20 start-page: 110 issue: 2 year: 2019 ident: pone.0280877.ref023 article-title: Late diagnosis, delayed presentation and late presentation among persons enrolled in a clinical HIV cohort in Ontario, Canada (1999–2013). publication-title: HIV Med doi: 10.1111/hiv.12686 |
| SSID | ssj0053866 |
| Score | 2.4610872 |
| Snippet | In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess short- and... Introduction In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess... Introduction In Europe, half of people living with HIV (PLWH) present late to care, with associated higher morbidity and mortality. This study aims to assess... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0280877 |
| SubjectTerms | Acquired immune deficiency syndrome Adult AIDS Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Antiviral agents Biological products industry Biology and Life Sciences Care and treatment CD4 antigen CD4 Lymphocyte Count Clinics Consent Cost assessments Costs Data collection Drugs Economic aspects Europe Evaluation Health aspects Health Care Costs Health risks Highly active antiretroviral therapy HIV HIV (Viruses) HIV Infections - diagnosis HIV Infections - drug therapy HIV Infections - epidemiology HIV testing Hospitalization Human immunodeficiency virus Humans Infections Laboratories Laboratory tests Medical care, Cost of Medical diagnosis Medicine and Health Sciences Morbidity Mortality Netherlands Netherlands - epidemiology Patient outcomes Public health United States |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQigMXRHk1UMAgJOCQlsRZP46lomovBfGoeoscP9qVFmfV7CL1V_CXmXG8YYMqlQO3VTyOdmfG42_W428Iee2nziovVc650zk6Ra6ltXnRlMKVtiqbxsdmE-LkRJ6dqc8brb6wJqynB-4Vt6dVI3ThlC2Zr5SWjVCw6TINqYzyXnmMvoB61slUH4NhFXOeLsoxUewlu-wu2uB28TBRCjHaiCJf_xCVJ4t5210HOf-unNzYig7vkbsJQ9L9_rtvkVsu3CdbaZV29G2ikn73gPw6GPMxUx0s7S4Acufx47wN5zkGZ9pvbfRHf25DTdstQRo7EdFI0dFR_MeWYiv6-VWci_SSV87SxZ8LTIECBKZHx6cUC8roLFCAl3TjTvFD8v3w47eDozy1YMgNV-UyV8pZKadGSm2nXpYadjyLWUgFQKUwBddFyXWlmPKqkp5bVzVaauOY8BKgHXtEJgGUvk0oAjerrYYQUFWNV40rDa-8gSSwAUdSGWFre9Qm8ZNjm4x5HQ_dBOQpvXprtGKdrJiRfJi16Pk5bpD_gKYeZJFdOz4An6uTz9U3-VxGXqCj1P1V1SFG1PsC4ADgzfcsI6-iBDJsBCzhOderrquPP53-g9DXLyOhN0nIt6AOo9O1CfhNyNw1ktwZSUKcMKPhbXTrtVa6ugTkX0W8CzPXrn798MthGF-KZXnBtasko7hkoNfH_coYNMsgFWWQfmdEjNbMSPXjkTC7iATngJCELKZP_oetnpI7JeDSWGgvd8hkeblyz8ht83M56y6fx6jxG5HndVE priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Library of Science (PLoS) Journals Open Access dbid: FPL link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELeg8ICEgI2PFQYYhAR7yFjs1B-PY6LaJDQmPqa9RU5sb5W6pFpapP0V_MvcOW62TJuAt6o-V-n57vy7-O5nQt75kbPaK50I4UyCRpEYZW2SFkw6ZjNWFD5cNiH399XRkT64SBSvnOBzmX6MOt2c1ZXbxINAJeVtcodxIbCEa3zwZRl5wXeFiO1xN83sbT-Bpb-LxYPZtG6uA5pX6yUvbUDjh__76I_Igwg16XZrGyvklqtWyf32PR1t249WyUp07oZ-iAzUG4_J750-jTM1laXNCSD1JHyc1tVxgjGdtjsiPW2Pe2hZN3OQxguMaGD2aCi-6KV4g_30PMxFVspzZ-nsou-pooCc6e7eIcU6NDqpKKBSeqkV-Qn5Of78Y2c3iTc3JKXQbJ5o7axSo1IpY0deMQMbpcXkJQN8k5apMCkTJtNce50pL6zLCqNM6bj0ChAhf0oGFShtjVDEe9ZYA5EjywqvC8dKkfkScscC7E8PCV8uaF5GWnO8XWOah7M6CelNq-4cVyGPqzAkSTdr1tJ6_EX-E9pKJ4uk3OELWO48-nhudCFN6rRl3GfaqEJqwIfcQNatvdd-SF6jpeVth2sXWvJtCSgCYOoWH5K3QQKJOSqs_Dk2i6bJ974e_oPQ9289ofdRyNegjtLEbgv4T0j41ZNc70lCeCl7w2voF0utNDmDhCELMBlmLn3l-uE33TD-KFbzVa5eRBktFAe9Pmtdq9MshwyWQ9Y-JLLndD3V90eqyUngRQdgJVU6en7zE78g9xiA1FB1r9bJYH62cC_J3fLXfNKcvQrB5A-I4HZ0 priority: 102 providerName: Public Library of Science |
| Title | Characteristics and short- and long-term direct medical costs among adults with timely and delayed presentation for HIV care in the Netherlands |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36753495 https://www.proquest.com/docview/2774460012 https://www.proquest.com/docview/2774496837 https://pubmed.ncbi.nlm.nih.gov/PMC9907815 https://doaj.org/article/a9b7a1e9d23f49a8b796173a1069ff9f http://dx.doi.org/10.1371/journal.pone.0280877 |
| Volume | 18 |
| WOSCitedRecordID | wos000966728400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Agricultural Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest advanced technologies & aerospace journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYxgMSAjY-VhjFICTgIdvy0dh-Qmu1atVYiTqYBi-RE9vbpJKUpkXaX8G_zJ3jdguaAImXU1Wfq-ZyPv_Ovg9CXpuOVsJw4cWxlh4qhSe5Up6fBUwHKgqyzNhmE2w45KenInEHbpULq1zYRGuoVZnjGflOADglsrvz-8l3D7tG4e2qa6GxQtawSgIuzKTzdWGJYS3HsUuXC5m_497O9qQs9DZeKXLGGtuRrdq_tM2rk3FZ3QQ8f4-fvLYh9e__76M8IPccFKV7te6sk1u62CB363M8WqcnbZB1t_gr-tZVqH73kPzsNcs8U1koWp0Dkvfsx3FZnHlo82m9Y9Jv9XUQzctqBtzY4Ijayh8VxYNgih3ux5d2LlatvNSKTq7yogoKyJoeDE4oxqnRi4ICaqXXUpUfkc_9_U-9A891dvDyWAQzTwitOO_knEvVMTyQsJEqdG4iwD9-7sfSD2IZiVAYEXETKx1lkstch8xwQIzhY7JawFvcJBTxoJJKgmWJosyITAd5HJkcfMsM9FO0SLh4wWnuyp5j941xau_yGLg_tbhTVIvUqUWLeMtZk7rsx1_4u6g7S14s2m2_KKdnqbMBqRQZk74WKghNJCTPmAD8GErwyoUxwrTIC9S8tM6AXZqedI8BygAYuxu2yCvLgYU7CowMOpPzqkoHH0_-gel41GB645hMCeLIpcvGgGfCgmANzq0GJ5ifvDG8ietkIZUqvdJumLnQ_5uHXy6H8Ucx2q_Q5dzxiJiHINcn9VJbSjYEDzcEr75FWGMRNkTfHCkuzm3ddABejPudp3_-W8_InQCArI3M51tkdTad6-fkdv5jdlFN22SFjU6QnjJLOVDe89tkrbs_TEZte6YDtJ98AHrY3QZ6tHuIlCWWHretkYIZyeAo-fILQDiUqA |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxELZKQAIJAS2PBgo1CAQctu0-srYPCJVClagloFKq3Bbv2k4jpbshm4DyK_gn_EZmvI92UQVceuAWxeNVdjKPb-x5EPLUdLQShgsnDLV0UCgcyZVy3Nhj2lOBF8fGDptg_T4fDMTHJfKzqoXBtMrKJlpDrbIEz8g3PcApgfXOrydfHZwahber1QiNQiz29OI7hGz5q95b-H-fed7uu8OdrlNOFXCSUHgzRwitOO8knEvVMdyTYMQVAusAfK-buKF0vVAGwhdGBNyESgex5DLRPjMc0IoPz71ELoMdZ5hCxgZ1gAe2IwzL8jyfuZulNGxMslRv4BUmZ6zh_uyUgNoXtCbjLD8P6P6er3nGAe7e_N9Yd4vcKKE23S50Y5ks6XSFXC_OKWlRfrVClkvjltMXZQful7fJj51mG2sqU0XzY4hUHPtxnKVDB30aLRABPSmuu2iS5TOgxgFO1HY2ySkedNPZ6ESPF3YvduVcaEUnp3VfKYXIgXZ7RxTz8OgopYDK6ZlS7Dvk84Uw6i5ppSA1q4Qi3lVSSbCcQRAbEWsvCQOTQOwcg_6JNvErgYqSsq07ThcZR_aukkF4V7A7QjGMSjFsE6feNSnamvyF_g3Kak2LTcntF9l0GJU2LpIiZtLVQnm-CYTkMROAj33pboXCGGHaZB0lPSoqfGvTGm0zQFEA07f8NnliKbAxSYqZT0M5z_Oo9-HoH4g-HTSInpdEJgN2JLKsNoF3woZnDcq1BiWY16SxvIp6WXElj061CXZW-nb-8uN6GR-K2YypzuYljQi5D3y9V6h2zVkfIng_EJ02YQ2lb7C-uZKOjm1feACWjLud-3_-Wevkavfw_X603-vvPSDXPADttgqBr5HWbDrXD8mV5NtslE8fWeNGyZeLNgm_AKvJ41Y |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbhMxELZKQAgJAS0_DRRqEAg4bNv9tX1AqLRUjYpKRaGquCzetd1GSndDNgHlKXgfno4Zrzftogq49MAtiser7GT8zTe2Z4aQpybWShguvCTR0kOj8CRXyvOzgOlARUGWGdtsgu3u8sNDsTdHfja5MHitssFEC9SqzHGPfDUAnhJZ77xq3LWIvc2t18OvHnaQwpPWpp1GbSI7evodwrfqVW8T_utnQbD19uPGtuc6DHh5IoKxJ4RWnMc551LFhgcSAF0hyY7AD_u5n0g_SGQkQmFExE2idJRJLnMdMsOBuYTw3EvkMoMYEwO_vfhz4wUAR5LEpeqFzF91lrEyLAu9gseZnLGWK7QdA2Z-oTMclNV5pPf3u5tnnOHWzf9ZjbfIDUfB6Xq9ZubJnC4WyPV6_5LWaVkLZN6BXkVfuMrcL2-THxvt8tZUFopWxxDBePbjoCyOPPR1tGYK9KQ-BqN5WY1BGhs7UVvxpKK4AU7H_RM9mNq5WK1zqhUdnuaDFRQiCrrdO6B4P4_2CwpsnZ5J0b5DPl2Iou6STgEWtEgo8mAllQREjaLMiEwHeRKZHGLqDNal6JKwMa40d-XesevIILVnmAzCvlrdKZpk6kyyS7zZrGFd7uQv8m_QbmeyWKzcflGOjlKHfakUGZO-FioITSQkz5gA3hxKfy0RxgjTJcto9Wmd-TuD3HSdAbsC-r4WdskTK4EFSwq02SM5qaq09_7gH4T2P7SEnjshU4I6cumyUOCdsBBaS3KpJQmwm7eGF3GNNlqp0tOVBTObtXf-8OPZMD4UbzkWupw4GZHwEPR6r17mM82GENmHkYi7hLUAoKX69kjRP7b14oFwMu7H9__8s5bJVUCC9F1vd-cBuRYAl7fJCXyJdMajiX5IruTfxv1q9MjiHCVfLhoRfgHplexJ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characteristics+and+short-+and+long-term+direct+medical+costs+among+adults+with+timely+and+delayed+presentation+for+HIV+care+in+the+Netherlands&rft.jtitle=PloS+one&rft.au=Popping%2C+Stephanie&rft.au=Versteegh%2C+Lisbeth&rft.au=Nichols%2C+Brooke+E&rft.au=David+A.+M.+C.+van+de+Vijver&rft.date=2023-02-08&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=18&rft.issue=2&rft.spage=e0280877&rft_id=info:doi/10.1371%2Fjournal.pone.0280877&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |